Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Military legacy === The war was the harbinger of a new type of combat: guerrilla warfare. The counterinsurgency techniques and lessons learned (restriction of movement, containment of space, targeting of anything that could give sustenance to guerrillas, harassment through sweeper groups coupled with rapid reaction forces, sourcing and co-ordination of intelligence, and nurturing of native allies) were used by the British, and other forces, in future guerrilla campaigns including to counter Malayan communist rebels during the Malayan Emergency. In World War II the British adopted concepts of raiding from the Boer commandos when they set up special raiding forces, and in acknowledgement chose the name British Commandos.
=== Predicting IDPs by sequence === Separating disordered from ordered proteins is essential for disorder prediction. One of the first steps to find a factor that distinguishes IDPs from non-IDPs is to specify biases within the amino acid composition. The following hydrophilic, charged amino acids A, R, G, Q, S, P, E and K have been characterized as disorder-promoting amino acids, while order-promoting amino acids W, C, F, I, Y, V, L, and N are hydrophobic and uncharged. The remaining amino acids H, M, T and D are ambiguous, found in both ordered and unstructured regions. A more recent analysis ranked amino acids by their propensity to form disordered regions as follows (order promoting to disorder promoting): W, F, Y, I, M, L, V, N, C, T, A, G, R, D, H, Q, K, S, E, P. As it can be seen from the list, small, charged, hydrophilic residues often promote disorder, while large and hydrophobic residues promote order. This information is the basis of most sequence-based predictors. Regions with little to no secondary structure, also known as NORS (no regular secondary structure) regions, and low-complexity regions can easily be detected. However, not all disordered proteins contain such low complexity sequences.
Routine toxicology studies have provided no evidence that moxonidine has any teratogenic, mutagenic or carcinogenic potential. No evidence has been found of serious adverse effects on organs or organ systems, and the drug has not been shown to have deleterious effects on perinatal or postnatal growth and development.
Sources: en.wikipedia.org
Juan Calvete draws attention to this with explicitly when detailing the history of venomics. He declares that ''the last revolutions made in venomics research in the last decade (1989–1999) are the direct result of advancements made in proteomic-centered methods and the indirect result of more widely available and cost-effective forms of transcriptomics and bio-informatics analysis''. One of the first popular research topics of venomics was the pharmacological properties of the polypeptide toxins found in snake venom (Specifically, Elapidae and Hydrophidae) due to the neurotoxic properties and their ability to cause respiratory failure in animals. However, due to the lack of competent technology, less complex techniques (such dialysis to separate the venom), followed by simplistic chromatography and electrophoresis analysis, research was limited.
The Union for the Defense of the Motherland and Freedom (Russian: Союз защиты Родины и Свободы) was an underground anti-Bolshevik organization active during the early stages of the Russian Civil War. It was formally established in March 1918 under the leadership of Boris Savinkov, although the idea for the organization had emerged in late 1917. Its creation was supported by elements of the Volunteer Army, including Generals Lavr Kornilov and Mikhail Alekseev. The organization sought to coordinate anti-Bolshevik resistance and prepare armed uprisings in central Russia. It is best known for its role in organizing the Yaroslavl Uprising, the Rybinsk Uprising, the Murom Uprising, and the Elatma Uprising in 1918. Although it established branches in several Russian cities, it was largely destroyed following the suppression of these revolts. A successor organization, the People's Union for the Defense of the Motherland and Freedom, was reconstituted in exile in 1921 and continued anti-Bolshevik underground activity until it was dismantled by the Soviet secret police in 1924. Savinkov himself was arrested in 1924 and died in OGPU custody in 1925.
In over 50 cases between 1887 and the early 1990s, prosecutors charged Christian Scientists after adults and children died of treatable illnesses without medical care. The death in 1967 of five-year-old Lisa Sheridan of pneumonia, in Cape Cod, Massachusetts, was the first of several in the 20th century known within the church as the "child cases," according to Fraser. Her mother was convicted of manslaughter and sentenced to five years' probation. It was after this prosecution that the church began lobbying for religious exemptions. In 1977, 16-month-old Matthew Swan died of bacterial meningitis in Detroit, Michigan, after his parents were persuaded not to seek timely medical care; they responded by founding Children's Healthcare is a Legal Duty (CHILD) in 1983. Between 1980 and 1990, seven Christian Scientist parents in the United States were prosecuted; there were four convictions, two overturned. In 1988, 12-year-old Ashley King died in Phoenix, Arizona, after living for months with a tumor on her leg that had a 41-inch (1,000 mm) circumference. Her parents pleaded guilty to reckless endangerment. A prominent case in Massachusetts was Commonwealth v. Twitchell in 1990, which saw the parents of two-year-old Robyn Twitchell convicted of involuntary manslaughter after he died of peritonitis. The conviction was overturned; the appellate court ruled that the couple had "reasonably believed" they could rely on Christian Science prayer without being prosecuted.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.